Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting

News provided by

Nov 21, 2018, 16:05 ET

SUZHOU, China and HONG KONG and ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies for the treatment of cancers, hepatitis B and aging-related diseases, announced today that the Company will present clinical data of its novel BCR-ABL inhibitor HQP1351 in the upcoming 60th Annual Meeting of the American Society of Hematology (ASH). The principal investigator of the study, Qian Jiang, MD, Deputy Director of Peking University People's Hospital, Peking University Institute of Hematology, and Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, will give an oral report during the meeting. HQP1351 is a third-generation BCR-ABL inhibitor for the treatment of drug-resistant CML (Chronic Myeloid Leukemia).

Oral Report
Topic: Safety and Efficacy of HQP1351, a Third-Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor - Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
Number: 791
Speaker: Qian Jiang, MD
Time: Monday, December 3, 2018: 3:45 PM
Location: 6E (San Diego Convention Center)
Preview Link: https://ash.confex.com/ash/2018/webprogram/Paper119142.html

About HQP1351
HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral high-efficiency third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. Phase I clinical trials for patients with imatinib-resistant CML have been completed and Phase II clinical trials have been initiated.

About Ascentage Pharma
Ascentage Pharma is a globally-focused clinical-stage biopharmaceutical company developing small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

For further enquiries, please contact:
Hill+Knowlton Strategies
Joanne Lam / Morning Zhu
Tel: (852) 2894 6211 / 2894 6227
Email: [email protected] / [email protected]

SOURCE Ascentage Pharma